[Kangpu*] Announcement: Company's Second Multinational, Multicenter Pivotal Phase 3 Clinical Trial (CBL-0302) of New Drug CBL-514 Injection for Reducing Abdominal Subcutaneous Fat, Health Canada CTA Submission Completed Today
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Kangpu announced the completion of its Clinical Trial Application (CTA) to Health Canada for CBL-0302, the second pivotal Phase 3 trial of its new drug CBL-514 injection for reducing abdominal subcutaneous fat. The trial will enroll approximately 320 participants in the US, Canada, and Australia.